MCID: MYX005
MIFTS: 54

Myxoid Liposarcoma

Categories: Rare diseases, Cancer diseases, Gastrointestinal diseases, Oral diseases

Aliases & Classifications for Myxoid Liposarcoma

MalaCards integrated aliases for Myxoid Liposarcoma:

Name: Myxoid Liposarcoma 54 12 50 71 29 13 14
Myxoid/round Cell Liposarcoma 50 56 69
Liposarcoma, Myxoid 42 69
Liposarcoma 56 69
Mrcls 50 56
Liposarcoma Myxoid 52
Myxoliposarcoma 50
Mxlipo 71

Characteristics:

Orphanet epidemiological data:

56
liposarcoma
Prevalence: 1-9/100000 (Europe); Age of onset: All ages;
myxoid/round cell liposarcoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Adult; Age of death: adult;

HPO:

32
myxoid liposarcoma:
Inheritance somatic mutation


Classifications:



External Ids:

OMIM 54 613488
Disease Ontology 12 DOID:5363
MeSH 42 D018208
SNOMED-CT 64 27849002 404069006
MESH via Orphanet 43 D008080 D018208
UMLS via Orphanet 70 C0023827 C0206634
ICD10 via Orphanet 34 C49.9
MedGen 40 C0206634
UMLS 69 C0206634

Summaries for Myxoid Liposarcoma

NIH Rare Diseases : 50 myxoid liposarcoma is a subtype of liposarcoma, tumors that arise in the body’s fat tissue. other categories of liposarcoma include well-differentiated; dedifferentiated; round cell; and pleomorphic. round cell and myxoid liposarcomas are sometimes grouped together into one category known as myxoid/round cell liposarcoma (mrcls). in adults, liposarcomas are the most common type of soft tissue sarcoma. the cause of liposarcomas is not well-established but trauma has been implicated in some cases. myxoid liposarcomas generally arise in the lower extremities. symptoms may vary depending on the location of the tumor but may include swelling; decreased range of motion; numbness; fatigue; abdominal pain; weight loss; nausea; and vomiting. many patients with liposarcoma have no symptoms until the tumor is large and interferes with neighboring structures. when possible, surgical removal is the preferred treatment. in some cases, additional therapy may be indicated. the prognosis is generally favorable for those with a low grade myxoid liposarcoma with a small percentage of round cells. a significant round cell component is associated with a poorer prognosis.  although these tumors rarely spread, they can recur if not completely removed.  last updated: 6/24/2016

MalaCards based summary : Myxoid Liposarcoma, also known as myxoid/round cell liposarcoma, is related to liposarcoma and histiocytoma, and has symptoms including abdominal pain, gastrointestinal dysmotility and subcutaneous nodule. An important gene associated with Myxoid Liposarcoma is DDIT3 (DNA Damage Inducible Transcript 3), and among its related pathways/superpathways are Pathways in cancer and HTLV-I infection. The drugs Trabectedin and Dacarbazine have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and breast, and related phenotype is neoplasm.

OMIM : 54
Myxoid liposarcoma is a soft tissue tumor that tends to occur in the limbs (especially the thigh) of patients ranging in age from 35 to 55 years. It is defined by the presence of a hypocellular spindle cell proliferation set in a myxoid background, often with mucin pooling. Lipoblasts tend to be small and often monovacuolated and to cluster around vessels or at the periphery of the lesion (review by Dei Tos, 2000). (613488)

UniProtKB/Swiss-Prot : 71 Myxoid liposarcoma: A soft tissue tumor that tends to occur in the limbs (especially the thigh) of patients ranging in age from 35 to 55 years. It is defined by the presence of a hypocellular spindle cell proliferation set in a myxoid background, often with mucin pooling. Lipoblasts tend to be small and often monovacuolated and to cluster around vessels or at the periphery of the lesion.

Wikipedia : 72 A myxoid liposarcoma is a malignant adipose tissue neoplasm of myxoid appearance... more...

Related Diseases for Myxoid Liposarcoma

Diseases related to Myxoid Liposarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 113)
id Related Disease Score Top Affiliating Genes
1 liposarcoma 32.5 EWSR1 MDM2
2 histiocytoma 29.6 CXCL8 IL6 TP53
3 myxoid liposarcoma of the ovary 12.2
4 cellular myxoid liposarcoma 12.0
5 blunt duct adenosis of breast 10.7 EWSR1 HMGA2
6 transitional cell carcinoma 10.6 HMGA2 MDM2
7 transverse colon cancer 10.6 EWSR1 FUS HMGA2
8 thyroid cancer, nonmedullary, 4 10.6 DDIT3 EWSR1 FUS
9 primary pulmonary lymphoma 10.6 CDK4 MDM2
10 epidural neoplasm 10.6 CDK4 MDM2
11 reactive arthritis 10.5 CDK4 MDM2
12 skin lipoma 10.5 CDK4 MDM2
13 coronary aneurysm 10.5 CDK4 MDM2
14 acute cholinergic dysautonomia 10.5 MDM2 TP53
15 metachronous osteosarcoma of the bone 10.5 CDK4 MDM2
16 cutaneous liposarcoma 10.4 CDK4 DDIT3 MDM2
17 oculomotor nerve paralysis 10.4 CXCL8 IL6
18 thymus large cell carcinoma 10.4 EWSR1 FUS
19 mucinous intrahepatic cholangiocarcinoma 10.4 CDK4 HMGA2 MDM2
20 common peroneal nerve lesion 10.4 CXCL8 IL6
21 kidney lipoma 10.4 CDK4 HMGA2 MDM2
22 lipoic acid biosynthesis defects 10.4 CDK4 MDM2
23 rhabdomyosarcoma 2, alveolar 10.4 CDK4 EWSR1 MDM2
24 drug rash with eosinophilia and systemic symptoms 10.4 CXCL8 IL6
25 spirillary rat-bite fever 10.3 CXCL8 IL6
26 rectum squamous cell carcinoma 10.3 MDM2 TP53
27 vulvar liposarcoma 10.3 FUS MDM2 TP53
28 lichen nitidus 10.3 MDM2 TP53
29 sparse hair ptosis mental retardation 10.3 EWSR1 MDM2 TP53
30 mediastinum rhabdomyosarcoma 10.3 EWSR1 MDM2 TP53
31 superior vena cava angiosarcoma 10.3 HMGA2 MDM2 TP53
32 median neuropathy 10.2 CDK4 DDIT3 FUS MDM2
33 cholelithiasis 10.2 CDK4 DDIT3 FUS MDM2
34 parkinsonism with dementia of guadeloupe 10.2 ATF1 EWSR1
35 rnase t2-deficient leukoencephalopathy 10.2 CDK4 MDM2 TP53
36 brain ischemia 10.2 NFKBIZ TP53
37 breast epithelioid hemangioma 10.2 CDK4 MDM2 TP53
38 spondyloepimetaphyseal dysplasia, isidor type 10.2 ERG EWSR1 FUS
39 sarcosinemia 10.2 CDK4 FUS HMGA2 MDM2
40 ascaridiasis 10.2 CDK4 MDM2 TP53
41 enamel hypoplasia cataract hydrocephaly 10.2 CDK4 MDM2 TP53
42 macular holes 10.2 ATF1 HMGA2
43 localized osteosarcoma 10.2 CDK4 MDM2
44 schwannoma of ureter 10.2 CXCL8 IL6
45 brown-vialetto-van laere syndrome 10.2 CDK4 EWSR1 TP53
46 sarcoma 10.2
47 unilateral retinoblastoma 10.2 CDK4 MDM2 TP53
48 pharynx cancer 10.2 CDK4 MDM2 TP53
49 cystic lymphangioma 10.2 CDK4 MDM2 TP53
50 synovium cancer 10.2 CXCL8 IL6 PRG4

Graphical network of the top 20 diseases related to Myxoid Liposarcoma:



Diseases related to Myxoid Liposarcoma

Symptoms & Phenotypes for Myxoid Liposarcoma

Clinical features from OMIM:

613488

Human phenotypes related to Myxoid Liposarcoma:

56 32 (show all 11)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abdominal pain 56 32 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0002027
2 gastrointestinal dysmotility 56 32 occasional (7.5%) Occasional (29-5%) HP:0002579
3 subcutaneous nodule 56 32 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0001482
4 fatigue 56 Occasional (29-5%)
5 weight loss 56 Occasional (29-5%)
6 varicose veins 56 Occasional (29-5%)
7 sarcoma 56 Very frequent (99-80%)
8 paresthesia 56 Occasional (29-5%)
9 nausea and vomiting 56 Occasional (29-5%)
10 abnormality of the kidney 56 Occasional (29-5%)
11 myxoid liposarcoma 32 HP:0012268

MGI Mouse Phenotypes related to Myxoid Liposarcoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.1 CDK4 DDIT3 ERG IL6 MDM2 TP53

Drugs & Therapeutics for Myxoid Liposarcoma

Drugs for Myxoid Liposarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 57)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trabectedin Approved, Investigational Phase 3,Phase 2,Phase 1 114899-77-3 108150
2
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166
3
Epirubicin Approved Phase 3 56420-45-2 41867
4
Etoposide Approved Phase 3 33419-42-0 36462
5
Gemcitabine Approved Phase 3 95058-81-4 60750
6
Ifosfamide Approved Phase 3 3778-73-2 3690
7
Mechlorethamine Approved Phase 3 51-75-2 4033
8
Docetaxel Approved May 1996, Investigational Phase 3 114977-28-5 148124 9877265
9 Alkylating Agents Phase 3,Phase 2,Phase 1
10 Anti-Bacterial Agents Phase 3,Phase 2
11 Antibiotics, Antitubercular Phase 3,Phase 2
12 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
13 Topoisomerase Inhibitors Phase 3,Phase 2
14 Anti-Infective Agents Phase 3,Phase 2
15 Antimetabolites Phase 3
16 Antimetabolites, Antineoplastic Phase 3
17 Antimitotic Agents Phase 3
18 Antineoplastic Agents, Phytogenic Phase 3
19 Antiviral Agents Phase 3
20 Etoposide phosphate Phase 3
21 Isophosphamide mustard Phase 3
22
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
23
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
24
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999
25
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
26
Everolimus Approved Phase 2 159351-69-6 6442177
27
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
28
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
29
Doxil Approved June 1999 Phase 2 31703
30
Maleic acid Experimental Phase 2 110-16-7 444266
31
Efatutazone Investigational Phase 2 223132-37-4
32 Antiemetics Phase 2
33 Anti-Inflammatory Agents Phase 2
34 Antineoplastic Agents, Hormonal Phase 2
35 Autonomic Agents Phase 2
36 BB 1101 Phase 2
37 Dexamethasone acetate Phase 2 1177-87-3
38 Gastrointestinal Agents Phase 2
39 glucocorticoids Phase 2
40 HIV Protease Inhibitors Phase 2
41 Hormone Antagonists Phase 2
42 Hormones Phase 2
43 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
44 Peripheral Nervous System Agents Phase 2
45
protease inhibitors Phase 2
46 Antibodies Phase 2
47 Antibodies, Monoclonal Phase 2
48 Immunoglobulins Phase 2
49 insulin Phase 2
50 Insulin, Globin Zinc Phase 2

Interventional clinical trials:

(show all 17)

id Name Status NCT ID Phase Drugs
1 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
2 Brostallicin Clinical Trial for Myxoid Liposarcoma Unknown status NCT00633165 Phase 2 Brostallicin
3 Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma Completed NCT00579501 Phase 2 Trabectedin;Dexamethasone
4 A Study of R1507 in Participants With Recurrent or Refractory Sarcoma Completed NCT00642941 Phase 2 RG1507
5 Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma Completed NCT02131480 Phase 2 Doxorubicin;Trabectedin
6 Rosiglitazone in Treating Patients With Liposarcoma Completed NCT00004180 Phase 2 rosiglitazone maleate
7 Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas Recruiting NCT02106312 Phase 2
8 Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma Recruiting NCT02821507 Phase 2 sirolimus and cyclophosphamide
9 A Pilot Study of NY-ESO-1ᶜ²⁵⁹T Cells in Subjects With Advanced Myxoid/ Round Cell Liposarcoma Recruiting NCT02992743 Phase 1, Phase 2
10 Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery Recruiting NCT02249949 Phase 2 efatutazone
11 Phase I-II Trial, Multicenter, Open, Exploring Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients Recruiting NCT02275286 Phase 1, Phase 2 Trabectedin
12 Trial of CMB305 and Atezolizumab in Patients With Sarcoma Active, not recruiting NCT02609984 Phase 2
13 Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial Active, not recruiting NCT01692496 Phase 2 Pazopanib
14 Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial Terminated NCT01876043 Phase 2 plitidepsin
15 Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery Completed NCT01477021 Phase 1 cyclophosphamide
16 NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Withdrawn NCT02059850 Phase 1 Cyclophosphamide
17 Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma Recruiting NCT01957709

Search NIH Clinical Center for Myxoid Liposarcoma

Cochrane evidence based reviews: liposarcoma, myxoid

Genetic Tests for Myxoid Liposarcoma

Genetic tests related to Myxoid Liposarcoma:

id Genetic test Affiliating Genes
1 Myxoid Liposarcoma 29

Anatomical Context for Myxoid Liposarcoma

MalaCards organs/tissues related to Myxoid Liposarcoma:

39
T Cells, Bone, Breast, Kidney, Thyroid, Ovary, Myeloid

Publications for Myxoid Liposarcoma

Articles related to Myxoid Liposarcoma:

(show top 50) (show all 296)
id Title Authors Year
1
FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma. ( 28637688 )
2017
2
Extensive left ventricular, pulmonary artery, and pericardial metastasis from myxoid liposarcoma 16 years after the initial detection of the primary tumour: a case report and review of the literature. ( 28866706 )
2017
3
High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma. ( 28947876 )
2017
4
Primary Myxoid Liposarcoma of the Upper Thoracic Spine in an Elderly Patient. ( 28936087 )
2017
5
High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth. ( 28654818 )
2017
6
PRG4 expression in myxoid liposarcoma maintains tumor cell growth through suppression of an antitumor cytokine IL-24. ( 28192118 )
2017
7
Resectable primary pleural myxoid liposarcoma with a pedicle: report of a rare case and literature review. ( 28449500 )
2017
8
Pleomorphic myxoid liposarcoma in an adolescent with Li-Fraumeni syndrome. ( 28160093 )
2017
9
MRI characteristics associated with high-grade myxoid liposarcoma. ( 28256200 )
2017
10
Unusual Asymptomatic Fluorodeoxyglucose Avid Pheochromocytoma in a Case of Myxoid Liposarcoma of the Extremity on (18)-F Fluorodeoxyglucose Positron Emission Tomography-computed Tomography. ( 28670184 )
2017
11
Cystic Pulmonary Myxoid Liposarcoma Mimicking Endobronchial Blood Clot. ( 27058719 )
2016
12
miR-135b, a key regulator of malignancy, is linked to poor prognosis in human myxoid liposarcoma. ( 27157622 )
2016
13
Whole-body magnetic resonance imaging in myxoid liposarcoma: A useful adjunct for the detection of extra-pulmonary metastatic disease. ( 26831007 )
2016
14
Clinical relevance of peroxisome proliferator-activated receptor-gamma expression in myxoid liposarcoma. ( 27401457 )
2016
15
Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation. ( 27270875 )
2016
16
Primary dumbbell-shaped epidural myxoid liposarcoma of the thoracic spine: A case report and review of the literature. ( 26893754 )
2016
17
Lipoblastoma presenting as a rapidly growing paravertebral mass and masquerading as myxoid liposarcoma on fine needle aspiration cytology. ( 26919610 )
2016
18
Efficacy of neoadjuvant hypofractionated radiotherapy in patients with locally advanced myxoid liposarcoma. ( 27026512 )
2016
19
Myxoid liposarcoma with pleomorphic cells: Report of two cases with molecular confirmation of FUS gene rearrangements. ( 27515548 )
2016
20
Myxoid liposarcoma of the foot: a study of 8 cases. ( 27806844 )
2016
21
Myxoid liposarcoma of the hand - A rare entity. ( 28018076 )
2016
22
Primary lesser sac myxoid liposarcoma: A case report. ( 27176503 )
2016
23
Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation. ( 26897615 )
2016
24
Sustained clinico-radiologic response to anti-cytotoxic T lymphocyte antigen 4 antibody therapy in metastatic myxoid liposarcoma. ( 27511215 )
2016
25
High-Grade Myxoid Liposarcoma (Round Cell Variant) in a Dog. ( 27665042 )
2016
26
Soft tissue uptake of 99mTc-MDP in a case of myxoid liposarcoma with breast metastasis. ( 28292146 )
2016
27
Myxoid Liposarcoma Originating In The Anterior Mediastinum. ( 28828769 )
2016
28
Axitinib Has Antiangiogenic and Antitumorigenic Activity in Myxoid Liposarcoma. ( 27822137 )
2016
29
Limb-sparing surgery as an alternative for limb amputation in an invasive myxoid liposarcoma - case report. ( 25866581 )
2015
30
Tumour-associated macrophages correlate with poor prognosis in myxoid liposarcoma and promote cell motility and invasion via the HB-EGF-EGFR-PI3K/Akt pathways. ( 25562433 )
2015
31
Prognostic factors for the recurrence of myxoid liposarcoma: 20 cases with up to 8 years follow-up. ( 25583234 )
2015
32
Myxoid liposarcoma with heterologous components: dedifferentiation or metaplasia? A FISH-documented and CGH-documented case report. ( 25747531 )
2015
33
The co-existence of a myxoid liposarcoma and leiomyoma in the same ovarian mass of a dog. ( 26522811 )
2015
34
Retroperitoneal perirenal myxoid liposarcoma. ( 25750026 )
2015
35
Comprehensive genetic analysis of a pediatric pleomorphic myxoid liposarcoma reveals near-haploidization and loss of the RB1 gene. ( 26647907 )
2015
36
Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma. ( 26225840 )
2015
37
Vulvar Myxoid Liposarcoma and Well Differentiated Liposarcoma With Molecular Cytogenetic Confirmation: Case Reports With Review of Malignant Lipomatous Tumors of the Vulva. ( 25851712 )
2015
38
Extensive lipoma-like changes of myxoid liposarcoma: morphologic, immunohistochemical, and molecular cytogenetic analyses. ( 25650275 )
2015
39
Primary myxoid liposarcoma of the ovary in a postpartum female: a case report and review of literature. ( 25760901 )
2015
40
Mesenteric metastases of purely myxoid liposarcoma: An unusual behavior of primary tumor depicted on fludeoxyglucose positron emission tomography/computerized tomography. ( 25589817 )
2015
41
Mediastinal Myxoid Liposarcoma with Intrapericardial Involvement and Large Pericardial Effusion. ( 26509343 )
2015
42
FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro. ( 26036639 )
2015
43
Metastasis of myxoid liposarcoma to fat-bearing areas: A case report of unusual metastatic sites and a hypothesis. ( 26622886 )
2015
44
Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma. ( 27499900 )
2015
45
Antiangiogenic activity of trabectedin in myxoid liposarcoma: Involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1. ( 24917554 )
2015
46
Successful salvage treatment of myxoid liposarcoma with multiple peritoneal seeding using helical tomotherapy-based intraperitoneal radiotherapy: a case report. ( 25930065 )
2015
47
A case of myxoid liposarcoma of the retroperitoneum: a challenging tumour for diagnosis and treatment. ( 25024863 )
2014
48
TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities. ( 24726063 )
2014
49
Myxoid liposarcoma of the spermatic cord: US and MR imaging findings. ( 23861011 )
2014
50
Immunohistochemical analysis of expressions of RB1, CDK4, HSP90, cPLA2G4A, and CHMP2B is helpful in distinction between myxofibrosarcoma and myxoid liposarcoma. ( 24788530 )
2014

Variations for Myxoid Liposarcoma

Cosmic variations for Myxoid Liposarcoma:

9 (show all 34)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM11333 TP53 soft tissue,fat,liposarcoma,myxoid-round cell c.499C>T p.Q167* 27
2 COSM44112 TP53 soft tissue,fat,liposarcoma,myxoid-round cell c.640C>T p.H214Y 27
3 COSM763 PIK3CA soft tissue,fat,liposarcoma,myxoid-round cell c.1633G>A p.E545K 27
4 COSM517 KRAS soft tissue,fat,liposarcoma,myxoid-round cell c.34G>A p.G12S 27
5 COSM1651756 KIT soft tissue,fat,liposarcoma,myxoid-round cell c.2334G>C p.K778N 27
6 COSM10647 TP53 soft tissue,fat,liposarcoma,pleomorphic c.404G>T p.C135F 19
7 COSM1651764 RB1 soft tissue,fat,liposarcoma,pleomorphic c.1818T>A p.Y606* 19
8 COSM24452 NF1 soft tissue,fat,liposarcoma,pleomorphic c.1105C>T p.Q369* 19
9 COSM28019 NF1 soft tissue,fat,liposarcoma,pleomorphic c.4006C>T p.Q1336* 19
10 COSM11245 TP53 soft tissue,fat,liposarcoma,NS c.430C>T p.Q144* 18
11 COSM44723 TP53 soft tissue,fat,liposarcoma,NS c.674T>C p.V225A 18
12 COSM10646 TP53 soft tissue,fat,liposarcoma,NS c.725G>A p.C242Y 18
13 COSM44094 TP53 soft tissue,fat,liposarcoma,NS c.716A>G p.N239S 18
14 COSM6901 TP53 soft tissue,fat,liposarcoma,NS c.559+1G>A p.? 18
15 COSM43663 TP53 soft tissue,fat,liposarcoma,NS c.826G>C p.A276P 18
16 COSM10941 TP53 soft tissue,fat,liposarcoma,NS c.730G>A p.G244S 18
17 COSM44512 TP53 soft tissue,fat,liposarcoma,NS c.740A>G p.N247S 18
18 COSM11059 TP53 soft tissue,fat,liposarcoma,NS c.713G>A p.C238Y 18
19 COSM10654 TP53 soft tissue,fat,liposarcoma,NS c.637C>T p.R213* 18
20 COSM775 PIK3CA soft tissue,fat,liposarcoma,NS c.3140A>G p.H1047R 18
21 COSM12458 PIK3CA soft tissue,fat,liposarcoma,NS c.1634A>C p.E545A 18
22 COSM760 PIK3CA soft tissue,fat,liposarcoma,NS c.1624G>A p.E542K 18
23 COSM21467 PIK3CA soft tissue,fat,liposarcoma,NS c.1612G>A p.D538N 18
24 COSM25083 PIK3CA soft tissue,fat,liposarcoma,NS c.1627A>G p.I543V 18
25 COSM532 KRAS soft tissue,fat,liposarcoma,NS c.38G>A p.G13D 18
26 COSM1290 KIT soft tissue,fat,liposarcoma,NS c.1727T>C p.L576P 18
27 COSM487 HRAS soft tissue,fat,liposarcoma,NS c.37G>A p.G13S 18
28 COSM480 HRAS soft tissue,fat,liposarcoma,NS c.34G>A p.G12S 18
29 COSM720 FGFR3 soft tissue,fat,liposarcoma,NS c.1949A>T p.K650M 18
30 COSM601 FGFR1 soft tissue,fat,liposarcoma,NS c.374C>T p.S125L 18
31 COSM5743 CTNNB1 soft tissue,fat,liposarcoma,NS c.117C>T p.A39A 18
32 COSM5708 CTNNB1 soft tissue,fat,liposarcoma,NS c.119C>T p.T40I 18
33 COSM5676 CTNNB1 soft tissue,fat,liposarcoma,NS c.122C>T p.T41I 18
34 COSM476 BRAF soft tissue,fat,liposarcoma,NS c.1799T>A p.V600E 18

Expression for Myxoid Liposarcoma

Search GEO for disease gene expression data for Myxoid Liposarcoma.

Pathways for Myxoid Liposarcoma

Pathways related to Myxoid Liposarcoma according to GeneCards Suite gene sharing:

(show all 22)
id Super pathways Score Top Affiliating Genes
1 12.53 CDK4 CXCL8 IL6 MDM2 TP53
2 12.28 ATF1 CDK4 IL6 TP53
3 12.23 ERG EWSR1 FUS HMGA2
4
Show member pathways
12.11 ATF1 CXCL8 IL6 TP53
5 11.97 ATF1 CDK4 MDM2 TP53
6 11.83 CXCL8 IL6 TP53
7 11.81 CDK4 MDM2 TP53
8 11.78 CDK4 CXCL8 IL6 TP53
9 11.76 CDK4 CXCL8 IL6
10 11.7 CDK4 MDM2 TP53
11 11.69 CXCL8 IL6 MDM2 TP53
12 11.62 ATF1 CXCL8 DDIT3 ERG EWSR1 FUS
13 11.54 CXCL8 IL6 MDM2 TP53
14 11.43 CXCL8 IL6 TP53
15 11.42 CDK4 CXCL8 MDM2 TP53
16 11.39 CXCL8 IL6 LRP1
17 11.31 CDK4 MDM2 TP53
18 11.2 CDK4 CXCL8 DDIT3 IL6
19 11.18 ATF1 DDIT3 TP53
20 11.11 CDK4 MDM2 TP53
21 10.92 ATF1 CDK4 MDM2 TP53
22 10.88 CXCL8 IL6

GO Terms for Myxoid Liposarcoma

Biological processes related to Myxoid Liposarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.85 ATF1 DDIT3 ERG HMGA2 IL6 TP53
2 positive regulation of apoptotic process GO:0043065 9.76 CDK4 HMGA2 IL6 TP53
3 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.58 DDIT3 HMGA2 IL6
4 positive regulation of protein export from nucleus GO:0046827 9.43 MDM2 TP53
5 PERK-mediated unfolded protein response GO:0036499 9.32 CXCL8 DDIT3
6 ER overload response GO:0006983 9.26 DDIT3 TP53
7 positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress GO:1990440 9.16 DDIT3 TP53
8 cellular response to actinomycin D GO:0072717 8.96 MDM2 TP53
9 response to antibiotic GO:0046677 8.8 IL6 MDM2 TP53

Sources for Myxoid Liposarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....